SBIR/STTR Research Award

Novel diagnostic test kit for a common syndrome of sensoryoverstimulation and cramping

Award identifier dca755a59562a1c1e7c686126136046477d62b87a11a1279ef3f19cc7d3da1d2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$230,505

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PhenoSolve LLC
Proposal award date
2018-07-10
Contract end date
2019-06-29
UEI
S3E7BCVRNRH4
Solicitation number
PA17-302
Topic code
NICHD

Research abstract

We have described an autosomal dominant syndrome that we callSensory Overstimulation SyndromeSOSThe most distinctive feature is the relative ineffectiveness of the local anesthetic lidocainea drug that blocks sodium channelsTheother key findingsbased on characterization ofpatientsare inattentionpainful muscle crampsand in femalessevere Premenstrual SyndromePMSWe estimate that SOS affectsof the entire populationormillion people in the USAwhich would make this syndrome among the most frequent causes of each of these diverse findingsproviding a genetic diagnosis for many who had previously been given non syndromic diagnoses such as ADHD or PMSWe have developed a biological test kit for the lidocaine ineffectiveness that is simplenon invasivenot painfuland nongameable by people who are normal but trying to obtain drugs of abuseThe diagnostic test kit prototype has been tested in a small studynIt has been protected with a patent filing and the FDA has asked us to validate the test kit in controlled trials before filing for marketing approvalThe importance of this test goes beyond a reaching a correct diagnosis and selecting alternate local anestheticsSOS patients with inattention respond well to potassium treatmentsreducing the need for stimulantsWe expect impact on drug abusepremenstrual syndromeand severe pain due to dental treatment in people with lidocaine ineffectivenessoften dismissed as if it were due todental anxietyWe propose the followingAimAssess reliability of taste based lidocaine test kit in a controlled trial and compare to lidocaine injectionThe ability of lidocaine oral gel to block tastesalt and sucrose solutionswill be assessed inadults and thenteenagershalf each with history of lidocaine ineffectivenessThe painless taste based lidocaine test will be evaluated in a randomized controlled trialtestedtimes on different days for each subject to determine the reproducibilityAt the FDAandapos s requesteach subject will also have thegold standardof injection of lidocaineassessed using painfor comparisonAimUse the test kit to determine the prevalence of lidocaine ineffectiveness in the general populationWe will use the test kit to determine the prevalence of lidocaine ineffectiveness by studyingindividuals ageswith no diagnosis of inattention to characterize the prevalence in the general populationexpect ineffective inAimUse the test kit to determine the prevalence of lidocaine ineffectiveness in patients with ADHDUsing the test kitwe will test the association between lidocaine ineffectiveness and inattention by studyingindividuals ageswith inattentionchosen from those who had been diagnosed with ADHDexpect ineffective inWe expect that this lidocaine test will provide a mechanistic biomarker for identification of the SOS syndrome in significant fractions of people currently diagnosed as having ADHD or PMSGiven the apparent high prevalence of SOSthe potential of the lidocaine taste test kit for commercialization is highas is the impact on public health This research is to validate a test for a common condition affecting the peripheral nervous system in which there is ineffectiveness of the local anesthetic lidocaineinattentionmuscle crampsandin femalespremenstrual syndromePMSThis condition begins in childhood and affectsof the entire populationmillion people in the USAAvailability of this test will allow major improvement in diagnosis and treatment of people currently diagnosed as having ADHDPMSanddental anxietyand by reducing use of stimulant drugswill reduce drug abuse

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2018). Reported award amounts total $530,010. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.